Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Achieve Life Sciences, Inc

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: $156.5M

Website

Clinical Trials

A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

Phase 1

Terminated

Conditions: Smoking Cessation

Interventions: Drug: Cytisine

First Posted Date: 2017-10-06

Last Posted Date: 2019-10-21

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 26

Registration Number: NCT03303911

Locations: 🇬🇧
Simbec Research Ltd, Cardiff, United Kingdom

A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine

Phase 1

Completed

Conditions: Smoking Cessation

Interventions: Drug: Cytisine

First Posted Date: 2017-08-31

Last Posted Date: 2019-02-26

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 24

Registration Number: NCT03268343

Locations: 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, United Kingdom

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Phase 1

Completed

Conditions: Cardiac Conduction and Repolarization

Interventions: Drug: Custirsen
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2013-06-11

Last Posted Date: 2016-10-10

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 155

Registration Number: NCT01874561

Locations: 🇺🇸
Teva Investigational Site 10565, Lenexa, Kansas, United States

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Phase 3

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Custirsen
Drug: Docetaxel

First Posted Date: 2012-06-28

Last Posted Date: 2016-07-01

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 700

Registration Number: NCT01630733

Locations: 🇺🇸
Florida Hospital, Orlando, Florida, United States
🇺🇸
University Cancer Institute, Soynton Beach, Florida, United States
🇺🇸
Joliet Oncology-Hematology Associates Ltd., Joliet, Illinois, United States

and more 78 locations

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: cabazitaxel
Drug: prednisone
Drug: custirsen sodium

First Posted Date: 2012-04-17

Last Posted Date: 2016-10-12

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 630

Registration Number: NCT01578655

Locations: 🇺🇸
Prostate Oncology Specialists, Marina Del Rey, California, United States
🇺🇸
University of California Davis Medical Center, Sacramento, California, United States
🇺🇸
Sharp Health Care, San Diego, California, United States

and more 90 locations

A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Custirsen, paclitaxel and carboplatin

First Posted Date: 2011-12-22

Last Posted Date: 2016-10-10

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 36

Registration Number: NCT01497470

Locations: 🇺🇸
Teva Investigational Site 002, Detroit, Michigan, United States
🇺🇸
Teva Investigational Site 001, Dallas, Texas, United States
🇺🇸
Teva Investigational Site 003, San Antonio, Texas, United States

and more 1 locations

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Phase 2

Completed

Conditions: Urologic Neoplasms
Metastatic Bladder Cancer
Urinary Tract Neoplasms

Interventions: Drug: OGX-427 600 mg
Drug: OGX-427 1000 mg
Drug: Placebo
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2011-10-18

Last Posted Date: 2016-10-07

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 183

Registration Number: NCT01454089

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States

and more 52 locations

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Custirsen
Drug: Docetaxel
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2010-08-25

Last Posted Date: 2016-10-14

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 1022

Registration Number: NCT01188187

Locations: 🇺🇸
Teva Investigational Site 100, Birmingham, Alabama, United States
🇺🇸
Teva Investigational Site 086, Los Angeles, California, United States
🇺🇸
Teva Investigational Site 263, Los Angeles, California, United States

and more 137 locations

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Phase 3

Terminated

Conditions: Hormone Refractory Prostate Cancer
Castrate-Resistant Prostate Cancer

Interventions: Drug: isotonic, 0.9% sodium chloride
Drug: custirsen sodium
Drug: docetaxel
Drug: cabazitaxel
Drug: prednisone

First Posted Date: 2010-03-10

Last Posted Date: 2016-10-12

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 14

Registration Number: NCT01083615

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: OGX-427
Drug: Docetaxel

First Posted Date: 2007-06-19

Last Posted Date: 2016-01-18

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 64

Registration Number: NCT00487786

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦
Juravinski Cancer Center, Hamilton, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy